Login to Your Account

Argen-x Adds $6.8M to Series B for Antibody Fragment Program

By Nuala Moran
Staff Writer

Monday, November 4, 2013
LONDON – Argen-x BV has raised €5 million (US$6.8 million) as an extension to its $37.1 million Series B financing round, allowing the company to accelerate a third antibody fragment program, ARGX-113, into clinical development.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription